Desk›Healthcare› Concord Biotech Ltd
Concord Biotech Ltd
BSE 543960 · NSE CONCORDBIO · ISIN INE338H01029 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹1,482.25
+0.01%
BSE close, 28 August 2026
₹15,506.74 cr
10.5 cr shares · Small cap
₹4,885.44 cr
as published
55.0× · 9.75×
EPS ₹26.95 · BV ₹152.03
1,055.07 / 263.27
₹ cr, as filed
15
4 selected · 27%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -15.2% |
|---|---|
| Against 52-week low | +50.2% |
| Day change | +0.01% |
| Size band | Small cap |
| Index membership | NIFTY 500 |
Valuation as published by BSE
| Earnings per share | ₹26.95 |
|---|---|
| Price / earnings | 55.00× |
| Price / book | 9.75× |
| Book value — derived, price ÷ P/B | ₹152.03 |
| Return on equity | 17.72% |
| Operating margin | 38.49% |
| Net margin | 23.49% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 17.73%
- ROE as published
- 17.72%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 260.52 | 61.19 | 5.85 | 38.49% | 23.49% |
| Mar-26 · Q | 325.89 | 90.02 | 8.60 | 42.32% | 27.62% |
| FY25-26 | 1,055.07 | 263.27 | 25.17 | 40.38% | 24.95% |
Quarter on quarter
- Revenue, quarter on quarter
- -20.1%
- Net profit, quarter on quarter
- -32.0%
- Operating margin, quarter on quarter
- -383 bps
Disclosure profile 15 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 2 |
| Concall Transcript | 1 |
| Results | 1 |
| Selected sub-total | 4 |
| Procedural | |
| Analyst / Investor Meet | 4 |
| AGM / EGM | 1 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| General | 1 |
| Newspaper Publication | 1 |
| Postal Ballot | 1 |
| Trading Window | 1 |
| Procedural sub-total | 11 |
| Total | 15 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
15 filings · 4 selected · busiest 2026-07-31
Filing rhythm · the twelve most recent
2026-07-312026-10-07
SelectedProcedural
Filings
15 in the window · 12 earlier on record
-
7 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance with regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith certificate received from RTA of the Company.
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
28 September 2026 ·
Closure of Trading Window
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and as per the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading ....
Insider Trading / SAST / Closure of Trading Window View filing →
-
25 September 2026 ·
Newspaper Publication
Newspaper advertisement for Notice of Postal Ballot dated September 23, 2026 and Remote E-Voting Information
Company Update / Newspaper Publication View filing →
-
24 September 2026 ·
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Pursuant to regulation 30 of the SEBI (LODR) Regulations, 2015, please find enclosed herewith a copy of the Postal Ballot Notice dated September 23, 2026 together with explanatory statement thereto.
AGM/EGM / Postal Ballot View filing →
-
23 September 2026 ·
Board Meeting Outcome for The Board Of Director At Its Meeting Held Today I.E. Wednesday, September 23, 2026, Has Inter-Alia Considered And Approved Issuance Of Bonus Shares & Inc rease In The Authorised Share Capital Of The Company.
The Board of Director at its meeting held today i.e. Wednesday, September 23, 2026, has inter-alia considered and approved Issuance of Bonus shares & Inc rease in the Authorised Share Capital ....
Board Meeting / Outcome of Board Meeting View filing →
-
18 September 2026 ·
Intimation Of Outcome Of U.S. Food And Drug Administration (USFDA) Inspection At Unit II - Valthera Formulation Facility Of The Company
Intimation of Outcome of U.S. Food and Drug Administration (USFDA) Inspection at Unit II - Valthera Formulation Facility of the Company.
Company Update / General View filing →
-
17 September 2026 ·
Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time ....
Company Update / Analyst / Investor Meet View filing →
-
21 August 2026 ·
Analyst / Investor Meet - Intimation
We would like to inform you that the officials of the Company will be attending an Investor Conference on 26th August 2026 as per the schedule and details in the file uploaded herewith.
Company Update / Analyst / Investor Meet View filing →
-
7 August 2026 ·
Earnings Call Transcript
Transcript of Q1 - FY27 Earnings call held on August 03, 2026
Company Update / Earnings Call Transcript View filing →
-
3 August 2026 ·
Analyst / Investor Meet - Outcome
The audio recording of the conference held on August 03, 2026 has been hosted on the website of the company and link to access the said recording is as follows: - Link : https://concordbiotech.com/wp-content/uploads/2026/08/Concord-Biotech-Q1-FY27-Earnings-Call-Audio-Recording.mp3 ....
Company Update / Analyst / Investor Meet View filing →
-
31 July 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
The 41st Annual General Meeting Meeting of the Members of the Company was held on Friday July, 31, 2026 at 12:00 Noon through VC/OAVM. The summary of the proceedings are published herewith.
AGM/EGM / AGM View filing →
-
31 July 2026 ·
Unaudited Standalone And Consolidated Financial Results For The First Quarter Ended On June 30, 2026
Unaudited Standalone and Consolidated Financial Results for the first quarter ended on June 30, 2026
Result / Financial Results View filing →
-
31 July 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Friday, July 31, 2026 - Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, July 31, 2026, on review and recommendation of Audit Committee of the Company, ....
Board Meeting / Outcome of Board Meeting View filing →
-
28 July 2026 ·
Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended from time to time, read with Para A of Schedule III thereto, We wish to inform you that the Company has arranged ....
Company Update / Analyst / Investor Meet View filing →
-
28 July 2026 ·
Board Meeting Intimation for Meeting To Be Held On Friday, July 31, 2026
Concord Biotech Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the unaudited Standalone and ....
Board Meeting / Board Meeting View filing →
RSS feed for Concord Biotech Ltd · the 50 most recent filings